In 2007, Soda and colleagues first identified a tyrosine kinase as a promising therapeutic target and diagnostic molecular marker for NSCLC, and this kinase accelerates the formation of a fusion gene comprising the portions of echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) in NSCLC cells [2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.